KemPharm (KMPH) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
KemPharm's (KMPH) KP511 Receives FDA Fast-Track Designation
May 10, 2016 8:35 AM EDTKemPharm, Inc. (Nasdaq: KMPH) announced that KP511, KemPharms prodrug of hydromorphone, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). KP511 is being developed as an abuse-deterrent, extended-release (ER) prodrug for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative... More
